Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Riecken, E.O.
Right arrow Articles by Rosewicz, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Riecken, E.O.
Right arrow Articles by Rosewicz, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:S197-S200, 1999
© 1999 European Society for Medical Oncology

Retinoids in pancreatic cancer

E.O. Riecken and S. Rosewicz

Dept. of Gastroenterology, Klinikum Benjamin Franklin Berlin, FRG, Germany

Correspondence to: Emst-Otto Riecken, MD, Dept. of Gastroenterology, Medizinische Klinik I, Klinikum Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin / FRG, Germany, E-mail: riecken{at}ukbf.fu-berlin.de

Prognosis of advanced, unresectable pancreatic adenocarcinoma remains dismal and has not significantly improved over the past 20 years. In a broad panel of preclinical experimental settings we have therefore evaluated the effects of retinoids on human pancreatic carcinoma cells in vitro and in vivo. We found that retinoid treatment results in inhibition of growth, induction of cellular differentiation and decreased adhesion to certain components of the extracellular matrix, all features compatible with a "less malignant" phenotype. Furthermore, retinoids act synergistically antiproliferative when combined with interferon-{alpha}. Using transient and stable genetic transfer studies we were able to identify two retinoid receptor subtypes responsible for mediating the growth inhibitory effects as well as retinoid sensitivity. In addition we observed a crucial functional interplay between the retinoid signalling pathway and the expression of a distinct protein kinase C isoenzyme, which determines the direction of the growth regulatory effects of retinoids. Based on these encouraging preclinical results we initiated a phase II clinical trial in which patients with advanced pancreatic carcinoma were treated with retinoic acid in combination with interferon-{alpha}. This therapeutic regimen was well tolerated and resulted in prolonged stable disease in approximately two thirds of the patients. In summary, these studies suggest that retinoids might be beneficial in the treatment of advanced pancreatic carcinoma patients based on their pleiotropic effects on tumor cell biology.

IFN-{alpha}, pancreas, protein kinase C, retinoids, retinoid receptor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.